Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 894.0 | 55 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 150.0 | 50 | |
| RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 610.0 | 52 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 256.5 | 50 | |
| N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 1025.5 | 50 | |
| RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 5923.0 | 55 | |
| RA1869 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 6275.5 | 40 | ||||
| N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4734.0 | 52 | |
| N2759 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4843.0 | 59 | ||||
| RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4634.0 | 55 | |
| RA1931 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 6114.0 | 52 | ||||
| N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 6861.0 | 54 | |
| N2586 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 6567.0 | 55 | ||||
| RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 60.0 | 50 | |
| RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 1130.5 | 54 | |
| N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 187.5 | 54 | |
| N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 1719.0 | 63 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 109.5 | 68 | |
| RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 823.5 | 50 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 173.0 | 62 | |
| N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 2455.0 | 57 | |
| RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 7968.0 | 68 | |
| RA1869 | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 8123.0 | 62 | ||||
| N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 7910.0 | 66 | |
| N2759 | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 8033.0 | 50 |